Immunic (IMUX) Operating Income (2013 - 2026)
Immunic (IMUX) posted Operating Income of -$33.2 million for Q1 2026, down 42.47% sequentially from -$23.3 million in Q4 2025, and down 23.9% YoY from -$43.7 million in Q1 2025.
Immunic (IMUX) Operating Income (2013 - 2026) Analysis & Trends
Immunic has reported Operating Income for 14 years, with the latest figure at -$33.2 million in Q1 2026.
- Quarterly Operating Income fell 23.9% year-over-year to -$33.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$109.6 million (down 8.56% YoY) and the FY2025 annual result came in at -$103.2 million, down 5.28% from the prior year.
- Operating Income declined to -$33.2 million in Q1 2026 per IMUX's latest filing, from -$23.3 million in the prior quarter.
- Over five years, Operating Income peaked at -$20.1 million in Q3 2022 and troughed at -$57.3 million in Q4 2022.
- A 5-year average of -$26.7 million and a median of -$25.0 million in 2023 frame the typical range for Operating Income.
- The sharpest annual moves came in 2022 and 2023: Operating Income tumbled 163.92% in 2022, then soared 59.21% in 2023.
- Over 5 years, Operating Income stood at -$57.3 million in 2022, then jumped by 59.21% to -$23.4 million in 2023, then decreased by 9.62% to -$25.6 million in 2024, then gained by 8.99% to -$23.3 million in 2025, then slumped by 42.47% to -$33.2 million in 2026.
- According to Business Quant data, Operating Income over the past three periods registered -$33.2 million, -$23.3 million, and -$26.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Immunic | 682.77 Mn | 682.77 Mn | - | -35.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -35.33 Mn |
| Mar 31, 2026 | -33.24 Mn |
| Dec 31, 2025 | -23.33 Mn |
| Sep 30, 2025 | -25.99 Mn |
| Jun 30, 2025 | -27.08 Mn |
| Mar 31, 2025 | -26.83 Mn |
| Dec 31, 2024 | -25.63 Mn |
| Sep 30, 2024 | -25.73 Mn |
| Jun 30, 2024 | -22.81 Mn |
| Mar 31, 2024 | -23.88 Mn |
| Dec 31, 2023 | -23.38 Mn |
| Sep 30, 2023 | -23.57 Mn |
| Jun 30, 2023 | -25.02 Mn |
| Mar 31, 2023 | -27.25 Mn |
| Dec 31, 2022 | -57.33 Mn |
| Sep 30, 2022 | -20.12 Mn |
| Jun 30, 2022 | -20.61 Mn |
| Mar 31, 2022 | -21.44 Mn |
| Dec 31, 2021 | -21.72 Mn |
| Sep 30, 2021 | -18.39 Mn |